Gene therapy stories
AI-driven real-time monitoring in cell and gene therapy manufacturing cuts costs, improves quality, and speeds patient access to advanced treatments globally.
Danish biotech firm Fuse Vectors has secured USD $5.2 million in pre-seed funding to advance its innovative cell-free gene therapy technology.
The peptide Active Pharmaceutical Ingredient market is poised for significant growth, driven by demand for targeted therapies and advances in synthesis technology.
A new mRNA method could deliver CAR-T therapy far sooner, and at lower cost, by making patients’ own cells do the engineering.
Australia's first viral vector manufacturing firm, VVMF, adopts SYSPRO Cloud ERP to enhance operations in advancing cell and gene therapies at Westmead Precinct.
Honeywell supports Peter Mac's AUD $105M Melbourne facility, Australia's first to commercialise CAR T-cell therapies, with advanced building tech.
